Background on AMIIF and its Relevance
The Mexican Association of Pharmaceutical Research Industries (AMIIF) is a crucial organization representing 33 pharmaceutical companies that produce innovative medicines. These companies participate in the government’s consolidated purchases, which account for approximately 20% of all medical pieces and molecules acquired. Although Mexico primarily consumes generic drugs, the inclusion of innovative medicines in these purchases signifies significant progress in pharmaceutical innovation with room for further growth.
AMIIF’s Call to Action: Ensuring Timely and Efficient Purchases
Karla Báez, the interim executive director of AMIIF, emphasized the importance of ensuring certainty and efficiency in acquiring medicines and medical devices for the proper functioning of the healthcare system and patient protection. She urged the federal government to avoid new delays in payments and secure budgets and clear processes for consolidated purchases of medicines and medical supplies from 2027 to 2028.
Current Payment Status
- 90% of the 2025 debt has been paid.
- Accumulated arrears from 2022 to 2024 remain unspecified.
Collaborative Efforts to Resolve Past Delays
Báez highlighted the significance of constant dialogue with representatives from IMSS, IMSS Bienestar, ISSSTE, national institutes, and some areas of the Health Secretariat, along with collaboration from the Anti-Corruption and Good Governance Department. These efforts led to resolving processes and regularizing payments for 2025, with nearly 10 meetings held in the last quarter of 2025.
Importance of Certainty for Investment and Healthcare
Báez stressed that certainty in regulatory aspects, payment terms, and transparent processes is vital for the healthcare system’s proper functioning and patient protection. She emphasized that meeting deadlines, such as the 90-day approval period stipulated by law, is crucial for maintaining trust among service providers and fostering Mexico’s reputation as a reliable investment destination, especially with the upcoming T-MEC review.
AMIIF’s Focus on Learning from Past Mistakes
Báez underscored the necessity of learning from past errors and improving coordination among various healthcare subsystems, including IMSS, IMSS Bienestar, ISSSTE, national institutes, and reference hospitals. She also highlighted the ongoing 2026 purchase process and the anticipation for the 2027-2028 purchases, emphasizing the importance of closing the 2026 purchase effectively to ensure high-quality acquisitions.
Upcoming Consolidated Purchase Process for 2027-2028
The consolidated purchase process for medicines and medical supplies from 2027 to 2028 is underway. Key activities include market research, gathering information from suppliers, understanding production capacity, and assessing availability and conditions. AMIIF, representing 33 innovative pharmaceutical companies, aims to ensure timely and high-quality deliveries, avoiding emergency purchases and ensuring sufficient quantities for efficient and continuous supply.
Key Questions and Answers
- What is AMIIF? The Mexican Association of Pharmaceutical Research Industries, representing 33 companies producing innovative medicines.
- Why is AMIIF’s call for timely payments important? Ensuring timely and efficient purchases of medicines and medical devices is crucial for the proper functioning of the healthcare system and patient protection.
- What percentage of purchases are innovative medicines? Innovative medicines account for approximately 20% of all medical pieces and molecules acquired through these consolidated purchases.
- What is the current payment status? 90% of the 2025 debt has been paid, but accumulated arrears from 2022 to 2024 remain unspecified.
- How has AMIIF addressed past delays? Through constant dialogue and collaboration with relevant government representatives, AMIIF resolved processes and regularized payments for 2025.
- Why is certainty important for investment and healthcare? Certainty in regulatory aspects, payment terms, and transparent processes fosters trust among service providers and enhances Mexico’s reputation as a reliable investment destination.
